Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq
He also currently serves as Chairman of the Board for EXO Incubator Inc. (private) and BlueSEQ Innovations Inc. (private).
- He also currently serves as Chairman of the Board for EXO Incubator Inc. (private) and BlueSEQ Innovations Inc. (private).
- “By using cell-free enzyme systems to produce biochemicals, we believe Invizyne can also significantly create new useful drugs and chemicals that can be commercially produced at competitive prices.
- The offering will be for 4,300,000 shares of common stock at a price per share of $4.00, for gross proceeds of $17.2 million.
- Invizyne has applied to list its common shares on The Nasdaq Stock Market under the ticker symbol "IZTC."